Avalyn’s Phase 1a trial of AP02 assessed clinical tolerability and pharmacokinetic profiles in three SAD cohorts, up to a maximum 2.0 mg dose in HVs; two BAL cohorts in HVs; and one cohort of patients ...

The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

A team from the Department of Cardiothoracic Surgery, Jawaharlal Nehru Medical College, Aligarh Muslim University, led by Prof. Mohd Azam Haseen, earned top honours at the IACTS Techno College CME ...

Steven Carlson, a student majoring in Engineering Science at Cecil College, recently had the opportunity to present his work ...